Zacks Initiates Coverage of Precipio With Outperform Recommendation

Zacks09-05

Zacks Investment Research has recently initiated coverage of Precipio, Inc. PRPO, assigning an "Outperform" recommendation to the company's shares. This bullish stance reflects the company's path to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465952199?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a","is_english":true,"pubTime":"2024-09-05 21:47","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2465952199","market":"us","top_or_hot":-1,"title":"Zacks Initiates Coverage of Precipio With Outperform Recommendation","media":"Zacks","content":"<div>\n<p>Zacks Investment Research has recently initiated coverage of Precipio, Inc. PRPO, assigning an \"Outperform\" recommendation to the company's shares. This bullish stance reflects the company's path to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zacks-initiates-coverage-precipio-outperform-134700151.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zacks Initiates Coverage of Precipio With Outperform Recommendation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZacks Initiates Coverage of Precipio With Outperform Recommendation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-05 21:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/zacks-initiates-coverage-precipio-outperform-134700151.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zacks Investment Research has recently initiated coverage of Precipio, Inc. PRPO, assigning an \"Outperform\" recommendation to the company's shares. This bullish stance reflects the company's path to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/zacks-initiates-coverage-precipio-outperform-134700151.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRPO","symbol_name":"Precipio, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/zacks-initiates-coverage-precipio-outperform-134700151.html","article_id":"2465952199","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465952199","pubTimestamp":1725544020,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Zacks Investment Research has recently initiated coverage of Precipio, Inc. PRPO, assigning an \"Outperform\" recommendation to the company's shares. This bullish stance reflects the company's path to profitability and robust positioning within the cancer diagnostics space.Precipio, currently operating from New Haven, CT, focuses on cancer diagnostics. The company, which aims to address the incidence of cancer misdiagnoses through the development of diagnostic products and services, operates clinical laboratories in New Haven, CT, and Omaha, NE, where it provides essential blood cancer diagnostics.Precipio saw a strong sequential revenue increase of 30% in second-quarter 2024, reaching $4.4 million. This growth was fueled by the company's Pathology and Products divisions, both of which are on the cusp of achieving profitability. The Pathology division has already hit breakeven, and the Products arm is expected to follow by the end of fourth-quarter 2024, positioning the company on track ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"PRPO":"Precipio, Inc."},"translate_title":"Zacks首次覆盖Precipio并给予跑赢大盘的推荐","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRPO":0.9},"content_text":"Zacks Investment Research has recently initiated coverage of Precipio, Inc. PRPO, assigning an \"Outperform\" recommendation to the company's shares. This bullish stance reflects the company's path to profitability and robust positioning within the cancer diagnostics space.\nPrecipio, currently operating from New Haven, CT, focuses on cancer diagnostics. The company, which aims to address the incidence of cancer misdiagnoses through the development of diagnostic products and services, operates clinical laboratories in New Haven, CT, and Omaha, NE, where it provides essential blood cancer diagnostics.\nPrecipio saw a strong sequential revenue increase of 30% in second-quarter 2024, reaching $4.4 million. This growth was fueled by the company's Pathology and Products divisions, both of which are on the cusp of achieving profitability. The Pathology division has already hit breakeven, and the Products arm is expected to follow by the end of fourth-quarter 2024, positioning the company on track for overall profitability soon after.\nDespite improvements in cash flow, the company's cash reserves remain at $1.3 million, leaving limited room for operational error.\nThe research report highlights several key factors that could drive Precipio’s future growth. These include its strategic partnerships with major players like Cardinal Health (which are key to scaling its product offerings, particularly its proprietary HemeScreen platform) and PRPO’s ongoing progress with the FDA, including a pre-submission meeting scheduled for later in 2024. Additionally, Precipio is making significant strides in its product division, particularly with the HemeScreen program, where it is on track to fully onboard three major customers by the end of 2024.\nHowever, potential investors should consider certain risks outlined in the report. PRPO faces risks from its operational losses and cash flow uncertainties. Medicare reimbursement poses a significant risk for Precipio, as delays or reductions in payments could severely impact the company’s financial stability. Moreover, dependence on key customer onboarding and competitive pressures in the diagnostics market also present potential headwinds.\nPrecipio’s stock has significantly outperformed its industry peers but has underperformed the broader market over the past year. Currently trading at low valuation multiples relative to industry standards, the stock presents a compelling entry point for investors, particularly when considering PRPO’s strategic market positioning and potential for profitability improvements.\nFor a comprehensive analysis of Precipio’s financial health, strategic initiatives, and market positioning, you are encouraged to view the full Zacks research report. This in-depth report provides a detailed discussion of the company's operational strategies, financial performance, and the potential risks and opportunities that lie ahead.\nRead the full Research Report on Precipio here>>> \nNote: Our initiation of coverage on Precipio, which has a modest market capitalization of $9.5 million, aims to equip investors with the information needed to make informed decisions in this promising but inherently risky segment of the market.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPrecipio, Inc. (PRPO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465952199"}